Back to Journals » Lung Cancer: Targets and Therapy » Volume 14

Commentary

Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

       
Total article views   HTML views PDF downloads Totals
2,460 Dovepress* 2,262+ 55 2,317
PubMed Central* 198 71 269
Totals 2,460 126 2,586
*Since 12 December 2023
Total mentioned Facebook Delicious Reddit Twitter Others
6 0 0 2 1 3

View citations on PubMed Central and Google Scholar